<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Physiotherapy, Balneology and Rehabilitation</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Physiotherapy, Balneology and Rehabilitation</journal-title><trans-title-group xml:lang="ru"><trans-title>Физиотерапия, бальнеология и реабилитация</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1681-3456</issn><issn publication-format="electronic">2413-2969</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">41594</article-id><article-id pub-id-type="doi">10.18821/1681-3456-2016-15-4-188-190</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The application of photodynamic therapy in the case of insufficient effect of the inhibitors of tumour necrosis factor in the patients with psoriasis</article-title><trans-title-group xml:lang="ru"><trans-title>Применение фотодинамической терапии при недостаточном эффекте блокаторов фактора некроза опухоли при псориазе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ponich</surname><given-names>E. S</given-names></name><name xml:lang="ru"><surname>Понич</surname><given-names>Е. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sokolovsky</surname><given-names>E. V</given-names></name><name xml:lang="ru"><surname>Соколовский</surname><given-names>Е. В</given-names></name></name-alternatives><bio xml:lang="en"><p>Department of Dermatovenerology with a clinic</p></bio><bio xml:lang="ru"><p>Кафедра дерматовенерологии с клиникой</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kruglova</surname><given-names>Larisa Sergeevna</given-names></name><name xml:lang="ru"><surname>Круглова</surname><given-names>Лариса Сергеевна</given-names></name></name-alternatives><bio xml:lang="en"><p>doctor med. sci., professor, chief research scientist Moscow Research and Practical Center of Dermatovenerology and Cosmetology Moscow Health Department</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, главный научный сотрудник МНПЦДК ДЗМ</p></bio><email>kruglovals@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Budgetary healthcare facility of Khanty-Mansiysky Autonomous Okrug - Yugra “Khanty-Mansiysky Clinical Dermatovenerological Dispensary”</institution></aff><aff><institution xml:lang="ru">БУ ХМАО - Югры «Ханты-Мансийский клинический кожно-венерологический диспансер»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.P. Pavlov Sankt-Peterburg First State Medical University, Russian Ministry of Health</institution></aff><aff><institution xml:lang="ru">«Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Moscow Research and Practical Center of Dermatovenerology and Cosmetology Moscow Health Department</institution></aff><aff><institution xml:lang="ru">Московский научно-практический центр дерматовенерологии и косметологии ДЗ г. Москвы</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2016</year></pub-date><volume>15</volume><issue>4</issue><issue-title xml:lang="en">VOL 15, NO4 (2016)</issue-title><issue-title xml:lang="ru">ТОМ 15, №4 (2016)</issue-title><fpage>188</fpage><lpage>190</lpage><history><date date-type="received" iso-8601-date="2020-07-23"><day>23</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Эко-Вектор"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjpbr.com/1681-3456/article/view/41594">https://rjpbr.com/1681-3456/article/view/41594</self-uri><abstract xml:lang="en"><p>Psoriasis is a systemic chronic inflammatory disease that affects in the first place the skin and occurs in 1-5% of the general population. The treatment of the patients presenting with this condition implies the application of the topical agent and biological preparations as well as phototherapy and systemic therapy. The patients suffering severe forms of psoriasis in whom systemic immunosuppressive therapy does not yield the desired effect are in need of the treatment with biological preparations. The use of the inhibitors of tumour necrosis factor-alpha produces the insufficient effect even in the case of the positive response, i.e. the psoriasis area and severity index (PASI) of approximately 50 scores (PASI 50). This article presents the results of the application of photodynamic therapy (PDT) for the treatment of 8 patients treated with the inhibitors of tumour necrosis factor-alpha in whom the PASI value of 50 was achieved within the first week after the onset of the treatment. In all these patients, a course of photodynamic therapy consisting of 2-3 procedures made it possible to increase the PASI values to 75 and even 100 scores. It is concluded that the patients showing positive but insufficient effect of biological therapy (PASI 50) need to be prescribed a course of photodynamic treatment in order to enhance the effectiveness of the biological therapeutic factors.</p></abstract><trans-abstract xml:lang="ru"><p>Псориаз является системным, хроническим, воспалительным заболеванием с преимущественным поражением кожи, которое встречается у 1-5% населения. Лечение больных псориазом предусматривает использование топических средств, биологических препаратов, методов фототерапии и системной терапии. Пациенты с тяжелыми формами псориаза при неэффективности системной иммуносупрессивной терапии нуждаются в биологических препаратах. Применение ингибиторов фактора некроза опухоли а (ФНОа) в 30% случаев дает недостаточный эффект при условии положительного ответа - индекса тяжести поражения псориазом (PASI) на уровне 50 (PASI 50). В статье приводятся данные о применении фотодинамической терапии (ФДТ) у 8 пациентов, получающих ингибиторы ФНОа и достигших PASI 50 к 1-й неделе терапии. Курс ФДТ из 2-3 процедур позволил добиться PASI 75 и PASI 100 у всех пациентов. Пациентам с положительным, но недостаточным эффектом биологической терапии (PASI 50) показан курс ФДТ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>psoriasis</kwd><kwd>systemic therapy</kwd><kwd>photodynamic therapy</kwd><kwd>inhibitors of the tumour necrosis factor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>псориаз</kwd><kwd>системная терапия</kwd><kwd>фотодинамическая терапия</kwd><kwd>блокаторы фактора некроза опухоли</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Drew G.S. Psoriasis. Prim. Care. 2000; 23 (2): 385-406.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009; 361: 496-509.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bremmer S., Van Voorhees A.S., Hsu S. et al. National Psoriasis Foundation. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. 2010; 63: 1058-69.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. M.: Издательство МДФ; 2014.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Tarstedt M., Rosdahl I., Berne B. et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta. Derm. Venereol. (Stockh.). 2005; 85: 1-5.</mixed-citation></ref></ref-list></back></article>
